Ipsen Biopharmaceuticals, Inc. Sustainability Profile
Ipsen Biopharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1929, Ipsen has established itself as a leader in the development of innovative therapies, particularly in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Dysport®, which are distinguished by their unique formulations and targeted delivery mechanisms. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. With a focus on patient-centric solutions, Ipsen continues to achieve notable recognition within the biopharmaceutical sector, driving advancements that improve patient outcomes globally.
DitchCarbon Score
How does Ipsen Biopharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipsen Biopharmaceuticals, Inc.'s score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipsen Biopharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Ipsen S.A., which cascades its climate commitments and emissions data. As part of its parent organisation's initiatives, Ipsen Biopharmaceuticals is aligned with various climate strategies, including those from the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both sourced from Ipsen S.A. at a cascade level of 2. While specific reduction targets or achievements for Ipsen Biopharmaceuticals are not detailed, the overarching commitments from Ipsen S.A. indicate a focus on sustainability and climate action. The company is involved in industry-standard initiatives aimed at reducing carbon footprints and enhancing environmental responsibility. As a subsidiary, Ipsen Biopharmaceuticals is expected to adhere to the climate strategies set forth by its parent company, reflecting a commitment to addressing climate change and reducing greenhouse gas emissions in line with global standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 14,316,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 4,343,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 121,718,000 | 00,000,000 | 00,000,000 | - | 00,000,000 |
How Carbon Intensive is Ipsen Biopharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Ipsen Biopharmaceuticals, Inc.'s Location?
Ipsen Biopharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Ipsen Biopharmaceuticals, Inc.'s Scope 3 emissions, which increased by 405% last year and decreased by approximately 25% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 67% of Scope 3 emissions.
Top Scope 3 Categories
Ipsen Biopharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ipsen Biopharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
